Evolving Landscape of HR+ Metastatic Breast Cancer Management
Closing out their review of treatment strategies for HR+ metastatic breast cancer, a panel of experts highlights ongoing investigations and future directions in care.
Related Articles
PET Imaging Agent Earns FDA Fast Track Designation in Recurrent Glioma
TLX101 is currently under assessment as a treatment for glioma in the IPAX-2 and IPAX-Linz studies.
FDA Approves Pegulicianine-Based Imaging for Breast Cancer Surgery
Results from the INSITE trial support the utility of pegulicianine fluorescence-guided surgery during breast cancer surgery.
Survival Outcomes Improve With TIL Presence in TNBC
An increased TIL count in the breast tissue was associated with improved distant recurrence-free survival in patients with triple-negative breast cancer.
Durvalumab Combo Yields OS Benefit in Advanced Biliary Tract Cancer
The phase 3 TOPAZ-1 trial of durvalumab plus chemotherapy showed a significant benefit vs chemotherapy alone for patients with advanced biliary tract cancer.
Response Observed With Savolitinib Combo in EGFR, MET, Osimertinib-Resistant NSCLC
A proteogenomic analysis found savolitinib plus osimertinib elicited a response in patients with EGFR-mutated, MET-amplified advanced NSCLC.
COVID-19 and Chemotherapy Association Holds in Pediatric Leukemia/Lymphoma
Pediatric patients with acute lymphoblastic leukemia/lymphoma were less likely to have severe COVID-19 infection.
Olutasidenib Yields Enduring Remissions in Previously Treated IDH1+ AML
Phase 2 findings support olutasidenib as a potentially “valuable” treatment option in IDH1-mutated acute myeloid leukemia.
The Role of a GPRC5D-Targeting Bispecific in Relapsed/Refractory MM
Beth Faiman, PhD, MSN, describes the role of a GRPC5D-targeting bispecific antibody, talquetamab, in the treatment of patients with relapsed/refractory multiple myeloma.
FDA Grants Accelerated Approval to T-DXd in Advanced HER2+ Solid Tumors
Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.
Post-Surgery Treatment of Localized Kidney Cancer
Sumanta Kumar Pal, MD, FASCO, joins Rohit Gosain, MD, and Rahul Gosain, MD, to discuss risk stratification and treatment practices for patients with localized kidney…